Navigation Links
Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America
Date:6/24/2010

Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s allogeneic adult stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.

(PRWEB) June 24, 2010 -- Stemedica Cell Technologies, Inc., a leader in allogeneic adult stem cell manufacturing, research and development announced today the appointment of César Amescua, MD as Medical and Regulatory Affairs Director for Latin America. Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.

Dr. Amescua is a member of the senior medical leadership at Groupo Angeles, one of the largest health care providers in all of Latin America. He is also President of the Mexican Association for the Study and Treatment of Pain. "I am excited and proud to be working with Stemedica. The company is a leader in the stem cell manufacturing field, and is bringing innovative technology to countries around the world. Latin America holds great promise for Stemedica’s products and services as Latin America seeks to address the epidemic of degenerative diseases and conditions that are bankrupting health care systems around the world."

Dr. Lev Verkh, Stemedica’s Chief Regulatory and Clinical Development Officer, commented, "We’re pleased and delighted to have Dr. Amescua joining our team at Stemedica. His medical leadership and his regulatory expertise will be critical in establishing clinical trials throughout Latin America using Stemedica stem cell products."

"With the rapid advancement of the clinical application and development of adult stem cell therapy around the world, the addition of Dr. Amescua’s medical leadership and regulatory expertise is critical in establishing extensive clinical trials for our products," said Dr. Nikolai Tankovich, Stemedica’s President and Chief Medical Officer.

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for its clinical trials for ischemic stroke. Stemedica is currently developing regulatory pathways for a number of medical indications using adult allogeneic stem cells. The Company is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc. contact Dave McGuigan at dmcguigan (at) stemedica.com.

###

Read the full story at http://www.prweb.com/releases/stemedica-stem-cells/human-clinical-trials/prweb4185804.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
2. Stemedica Completes Meeting with the FDA
3. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
4. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
5. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
6. Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
7. Stemedica Requests Pre-IND Meeting With FDA
8. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
9. Renowned Stem Cell Researcher Files Study Results With Stemedica
10. CIRM Completes Briefing Visit to Stemedica Cell Technologies
11. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America 
(Date:3/23/2017)... Research and Markets has announced the ... to their offering. ... The Global Market for Bioproducts Should Reach ... a CAGR of 8.9%, This research report ... seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and ...
(Date:3/23/2017)... , March 23, 2017  SeraCare Life ... global in vitro diagnostics manufacturers and clinical ... industry,s first multiplexed Inherited Cancer reference ... by next-generation sequencing (NGS). The Seraseqâ„¢ Inherited ... with input from industry experts to validate ...
(Date:3/23/2017)... 23, 2017  BioPharmX Corporation (NYSE MKT: BPMX), ... dermatology market, today reported financial results for the ... will provide an update on the company,s clinical ... "We are pleased to report that last ... said President Anja Krammer. "We achieved key clinical ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
Breaking Biology Technology:
(Date:3/9/2017)... VIEW, Calif. , March 9, 2017 ... 23andMe , the leading personal genetics company, are using ... now provide customers with personalized nutrition plans that consider ... but also genetic markers impacting how their body may ... food decision support platform uses biometrics such as Body ...
(Date:3/2/2017)... , March 2, 2017 Summary This ... Perrigo and its partnering interests and activities since 2010. ... Read the ... and Alliance since 2010 report provides an in-depth insight into ... sciences companies. On demand company reports are prepared ...
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: ... announced that Richard P. Moberg has resigned, ... co-President and Chief Financial Officer and Treasurer of Aware ... to serve as a member of the Board of ... , Aware,s co-Chief Executive Officer and co-President, General Counsel ...
Breaking Biology News(10 mins):